Ampyra and Warm type haemolytic anaemia - a phase IV clinical study of FDA data

Summary:

Warm type haemolytic anaemia is reported only by a few people who take Ampyra.

The phase IV clinical study analyzes which people take Ampyra and have Warm type haemolytic anaemia. It is created by eHealthMe based on reports of 75,087 people who have side effects while taking Ampyra from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 05, 2023

75,087 people reported to have side effects when taking Ampyra.
Among them, 3 people (0.0%) have Warm type haemolytic anaemia.

What is Ampyra?

Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. eHealthMe is studying from 75,227 Ampyra users for its effectiveness, alternative drugs and more.

What is Warm type haemolytic anaemia?

Warm type haemolytic anaemia (red cell destruction due to warm antibody self defence) is found to be associated with 171 drugs and 116 conditions by eHealthMe.

Number of Ampyra and Warm type haemolytic anaemia reports submitted per year:

Could Ampyra cause Warm type haemolytic anaemia?

Gender of people who have Warm type haemolytic anaemia when taking Ampyra *:

female: 100 %
male: 0.0 %

Age of people who have Warm type haemolytic anaemia when taking Ampyra *:

Common drugs people take besides Ampyra *:

Common side effects people have besides Warm type haemolytic anaemia *:

Loss Of Consciousness: 3 people, 100.00%
Anaemia (lack of blood): 1 person, 33.33%

Common conditions people have *:

Gait Disturbance: 3 people, 100.00%
Balance Disorder: 3 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ampyra and have Warm type haemolytic anaemia?

Check whether Warm type haemolytic anaemia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Warm type haemolytic anaemia and when was it recovered:

Warm type haemolytic anaemia in Ampyra

Expand to all the drugs that have ingredients of dalfampridine:

Warm type haemolytic anaemia and drugs with ingredients of dalfampridine

Alternative drugs to, pros and cons of Ampyra:

Ampyra (75,227 reports)

Common Ampyra side effects:

Drug ineffective: 8,776 reports
Weakness: 6,572 reports
Fatigue (feeling of tiredness): 6,118 reports
Urinary tract infection: 4,633 reports

Browse all side effects of Ampyra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Warm type haemolytic anaemia treatments and more:

Warm type haemolytic anaemia (205 reports)

COVID vaccines that are related to Warm type haemolytic anaemia:

All the drugs that are associated with Warm type haemolytic anaemia:

Warm type haemolytic anaemia (171 drugs)

All the conditions that are associated with Warm type haemolytic anaemia:

Warm type haemolytic anaemia (116 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.